STOCK TITAN

MariMed Files Preliminary Non-Offering Prospectus And Applies For Dual Listing on Canadian Securities Exchange

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

MariMed, Inc. (OTCQX: MRMD) has filed a preliminary non-offering long form prospectus with securities regulatory authorities in Ontario and British Columbia. This Prospectus aims for a dual listing of its common shares on the Canadian Securities Exchange (CSE). CEO Robert Fireman expressed optimism about the potential listing, believing it will enhance liquidity and attract more retail and institutional investors. However, there is no guarantee of receiving final approval from regulators or the CSE.

Positive
  • Application for dual listing on the Canadian Securities Exchange could enhance liquidity for shareholders.
  • Potential access to a larger pool of retail and institutional investors.
Negative
  • No guarantee of receiving final prospectus approval from regulators.
  • CSE acceptance of common shares listing is uncertain.

NORWOOD, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- MariMed, Inc. (OTCQX: MRMD) (“MariMed” or the “Company”), a leading multi-state cannabis operator focused on improving lives every day, today announced that it has filed a preliminary non-offering long form prospectus (the “Prospectus”) with the securities regulatory authorities in the Provinces of Ontario and British Columbia. No securities are being sold pursuant to the Prospectus and no proceeds are being raised.

The Company also announced that it has applied to list its common shares (“Common Shares”) on the Canadian Securities Exchange (the “CSE”). Listing and trading of the Common Shares will be subject to the Company fulfilling all the CSE’s listing requirements and the Company being receipted for a final prospectus with the securities regulatory authorities in the Provinces of Ontario and British Columbia.

“We are excited to announce this significant milestone of applying for a dual listing on the CSE,” said Robert Fireman, Chief Executive Officer of MariMed. “We believe the potential trading of our Common Shares on the CSE will increase liquidity for our shareholders, and provide access to a significant pool of prospective retail and institutional investors in addition to our current long-term investors we have on the OTCQX market.”

A copy of the Prospectus is available under the Company’s profile on SEDAR at www.sedar.com. There can be no guarantee that a receipt for the final prospectus will be obtained from the securities regulatory authorities in the Provinces of Ontario and British Columbia or that the CSE will accept the listing of the Common Shares.

ABOUT MARIMED
MariMed Inc., a multi-state cannabis operator, is dedicated to improving lives every day through its high-quality products, its actions, and its values. The Company develops, owns, and manages seed to sale state-licensed cannabis facilities, which are models of excellence in horticultural principles, cannabis cultivation, cannabis-infused products, and dispensary operations. MariMed has an experienced management team that has produced consistent growth and success for the Company and its managed business units. Proprietary formulations created by the Company’s technicians are embedded in its top-selling and award-winning products and brands, including Betty's Eddies, Nature’s Heritage, Bubby’s Baked, K Fusion, Kalm Fusion, and Vibations: High + Energy. For additional information, visit www.marimedinc.com.

For More Information, Contact:

Investor Relations:
Steve West, Vice President, Investor Relations
Email: ir@marimedinc.com

Media Contact:
Howard Schacter, Chief Communications Officer
Email: h.schacter@marimedinc.com


FAQ

What is the recent announcement by MariMed regarding the Canadian Securities Exchange?

MariMed announced it filed a preliminary non-offering long form prospectus to apply for a dual listing of its common shares on the Canadian Securities Exchange.

Will MariMed raise funds through the recently filed prospectus?

No, the prospectus is preliminary and no securities are being sold or proceeds raised.

What are the implications of the dual listing for MariMed shareholders?

The dual listing could increase liquidity and attract additional retail and institutional investors.

Is final approval for MariMed's prospectus guaranteed?

There is no guarantee that the final prospectus will be approved by securities regulatory authorities.

What is the stock symbol for MariMed?

The stock symbol for MariMed is MRMD.

MARIMED INC

OTC:MRMD

MRMD Rankings

MRMD Latest News

MRMD Stock Data

55.29M
280.32M
14.03%
0.3%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Norwood